Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
t57,
39 working days left excluding Holidays, until the end of the year, after today.
I think we see the opinion very soon if Judge Meyers is writing the opinion. She is one of the fastest on writing opinions.
She had the most questions so it might be logical it was assigned to her.
Boing X 2
pollyvonwog,
From NVS PR
"Biopharmaceuticals (which include biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 28% (cc) to USD 186 million, including continued progress of the newly launched Glatopa.”
They seem to think Glatopa is having continued progress. Now I am anxious to hear how much we earned.
The only thing I can think of is, improving over the actual sales after the initial stocking.
Boing X 2
t57,
Thank you. We will find out our share shortly.
Note this this morning,
Bid: 16.41 x 2700
Ask: 16.42 x 1300
I saw someone trying to make a buy at 16.53 x 9700 yesterday. Not exactly pocket change.
Notice the last three short positions,
Read more: http://www.nasdaq.com/symbol/mnta/short-interest#ixzz3plkQVxqM
Short position had been going up each two weeks. Dropped 700,000 this last two weeks. It appears they are trying to cover.
They messed up and it appears they want out before the CAFC ruling. Who would be selling and giving their shares away right before the ruling now and preventing a possible short squeeze?
Two months or less now to the ruling.
Institutional figures are starting to roll in and it appears they are still buying. So far only two sold out. Many numbers yet to be reported to get the total for the last quarter.
http://www.nasdaq.com/symbol/mnta/institutional-holdings
Boing X 2
jbog,
Thank you.
Boing X 2
pollyvonwog,
Thank you for posting the figures each week.
Can you help me out on the last TRX number 11,000 some. Do you know what time frame that number will cover ?
Ie. Oct? or for the last quarter? or year to date? I did a search without much luck over than it covers a time frame.
Thank you in advance.
Boing X 2
New pre grant patent application 10/22
MODIFIED GLYCOPROTEINS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Boing X 2
imnot6,
Thank you for the information.
That does not mean they should not be following up with the recent information and a possible track to a new improved potential that has just had a PR on the potential improvement. We should explore all avenues for new drugs when one gets a PR like this on bad disease like this.
Might not work, but one should find out if there is a possibility that it might work with MNTA. Stay ahead of the curve.
Yes they are working on it, but I have not seen a PR like this before.
Boing X 2
Dew Diligence,
OK. Thank you.
Let us talk to them about going for a regular approval as our HSIVig is 10 fold more effective.
I would like to see a test with our HSIVig and how it improves vs. what they are testing with now.
That would be a monster market if it improves the outcome over what they are currently testing with for an outcome.
Boing X 2
tony111,
I agree!
Boing X 2
HSIVIg information,
http://www.prnewswire.com/news-releases/sutter-memory-clinic-study-shows-ivig-could-be-key-to-alzheimers-cure-300157925.html
The potential would be big for MNTA. MNTA might want to talk with them. With our improved HSIVIg, if applicable, it would be a great one to get orphan drug status on this devastating disease.
Found the above after a great week of Trophy Trout fishing at the San Juan River in New Mexico. PR came out the day my BIL and I left.
Boing X 2
MS News.
"MS News Today ?@MSNewsToday 5h
5 hours ago
Glatiramer acetate 40mg injection site reaction is the most frequent adverse event #MSNewsToday #ECTRIMS2015 “
“A group of researchers are currently tackling the prevalence of Multiple Sclerosis outside Europe and North America, as Prof. David Miller highlighted, “Studies from several parts of the world, in particular some Asian and Arab countries, Iran, Latin America as well as Australia and New Zealand, demonstrate an increase in the prevalence of MS around the world over time.”
Boing X 2
More interesting after hour trades tonight.
Big blocks being bought after hours. 59K + bought in one block. Just pocket change? I hope it is a fund i am in that is buying and drying up the shares. I hope they hang tight to the shares.
With the institutions having 89+ percent right now it is not going to take but a few more large funds trying to establish large positions to possibly make our shares scarce.
We should have the figures rolling in on the third quarter institutional buying, selling and holding in 8 days .
http://www.nasdaq.com/symbol/mnta/after-hours
One more day closer to the CAFC opinion.
Boing X 2
Most Interesting After Hour Trades
Look at the last trades tonight. 19,600 buy at $16.9576 and last trade 500 at 17.42. Up .89 cents Hmmnn! I saw the up .89 cents and had to check it out.
I know After Hours Trades can have wild swings but that much for a large order. Someone got their clock cleaned or knows something and wanted in bad.
Note, most of the trades in the 16.52 range up to close to the end of trading.
Read more: http://www.nasdaq.com/symbol/mnta/after-hours#ixzz3nqUHMJ1u
Boing X 2
DewDiligence,
Thank you for your time and work on updates.
Humira
" A year’s worth of continuous treatment with the standard dosage of 40mg every other week costs $13,000 to $14,000.”
Humira brought in about $12.5 billion last year.
Phase 111 trial. My favorite words at my age.
Another day closer to a CAFC opinion.
Boing X 2
mouton29,
Thank you. Did not catch the lapsed. I did see it had been filed back then.
Boing x 2
Patent Application in Australia Prostate Cancer Marker
http://www.ipaustralia.com.au/applicant/momenta-pharmaceuticals-inc/patents/AU2003299730/
Boing X 2
floblu14,
Thank you for the feedback.
Bring it on!
I had to laugh when I looked back at my message and my error on my handle. I guess I was in a Halloween mode. Booing?
Boing X 2
Biopearl,
Just picked this up on Biopharma Chatter
"$MNTA: Wall Street analysts expect MNTA to grow earnings per share by 86.90% annually this year and 512.00% next year, based on the averages of all analyst estimates. For the next five years, analysts forecast N/A annual EPS growth for MNTA. In the past five years, MNTA's annual EPS growth was 0.00%. MNTA's price/earnings (P/E) ratio is -69.72, and its price/earnings to growth (PEG) ratio is N/A."
Hope they are right! We will be well on our way.
Boing X 2
biopearl,
You are most welcome!
That is a good thought on the message to Amphastar by Wheeler.
Another day closer to the CAFC opinion.
I noticed that Humana has in some locations put Glatopa as preferred over Copanone like in KY.
There were many additions late August and September which should help this last quarter that we are now starting.
Boing X 2
Pre Grant Patent Application 10/1
ANALYSIS OF DISULFIDE BONDS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Booing X 2
Interesting recent video I found on Momenta.
http://www.boston.com/business/news/2015/09/28/globe-recipe-for-success-momenta/cbhgJ0F0tZbgGp5lMPwzSN/video.html
Considering the source, I would say this is big. Note this is for 2016.
https://www.express-scripts.com/art/open_enrollment/GASHBPRXPDFS_PrefDrugListAZ.pdf
I just noticed on this health plan Glatopa is mandatory as the drug to be filled. Column 2, Copaxone not on the list.
https://www.valleyhealthplan.org/sites/grp/pn/Pharm/Documents/Pharmacy/VHP_EMP_Formulary%2009.01.2015%20MSP.pdf
Not added until 9/1 so likely no impact on third quarter. Page 4,
http://www.lighthouseguild.org/wp-content/uploads/2014/10/Formulary-Changes6.pdf
My guess is Sandoz is setting up for 2016. A lot of negotiations go on for a following year. I am thinking they did not want to give the store away with approval half way through the year. Plus price of medicines likely to be an issue for 2016.
Another day closer to the CAFC opinion.
Boing X 2
DewDiligence,
Thank you.
I just hate CA litigation. I have been involved with litigation there for years. The stories I could tell!
4 times to the CA Supreme Court to win a case that should have been won the first time. Had to spell out every reason why we were right, again and again, until they got it.
I was already thinking of having the venue moved but, as AMPH headquarters is in CA not sure that will happen.
Right you are, we need Mouton to jump in here.
Boing X 2
DewDillegence,
Thank you very much!!! Have you heard of this suit?
Amphastar files a new suit against us.
It would seem a PR would be warranted over this. I checked and I am not seeing any PR.
I hate to find out this kind of thing by me searching the net. Is anyone aware of information on this new suit?
Just filed 9/17 this month in CA.
https://dockets.justia.com/docket/california/cacdce/5:2015cv01914/628417
Amphastar Pharmaceuticals, Inc. et al v. Momenta Pharmaceuticals, Inc. et al
Anti-Trust | California Central
Order
STANDING ORDER REGARDING NEWLY ASSIGNED CASES by Judge R. Gary Klausner. Refer to the Court's order for details. (pso)
Misc | Filed: September 17, 2015 | Entered: September 17, 2015
Amphastar Pharmaceuticals, Inc. et al v. Momenta Pharmaceuticals, Inc. et al
Anti-Trust | California Central
Civil Cover Sheet (CV-71)
CIVIL COVER SHEET filed by Plaintiffs Amphastar Pharmaceuticals, Inc., International Medication Systems Ltd.. (Weir, Jan)
Misc | Filed: September 17, 2015 | Entered: September 17, 2015
Amphastar Pharmaceuticals, Inc. et al v. Momenta Pharmaceuticals, Inc. et al
Anti-Trust | California Central
Corporate Disclosure Statement
CORPORATE DISCLOSURE STATEMENT filed by Plaintiffs Amphastar Pharmaceuticals, Inc., International Medication Systems Ltd. (Weir, Jan)
Boing X 2
Floblu14,
I checked back on last quarter and with 12 days of sales we netted 19M and had to pay 9M in legal fees last quarter. I don’t think the whisper numbers estimates are that unreasonable with us having a full quarter sales and no 9M launch legal fee deduction.
It also appears cheap selling of our stock might be drying up. Thank’s to whomever sold me my shares.
One would hope the drug rep’s were busting their buns to get orders placed before the end of the quarter. As there were not large stocking orders placed at launch, per the 2nd qtr cc,
one would hope there are larger and additional re stocking orders taking place the last 90 days.
United HealthCare and many others were not on board during the 2nd quarter. Not long to find out.
Boing X 2
Floblu14,
Don’t shoot the messenger. I am not sure I trust Yahoo numbers. They always have an one analyst that is so low it throws the totals off.
Here is what I found. Time will tell shortly.
They did have higher sales for most of this quarter. They don’t have the 9M in legal fees this quarter.
Boing X 2
$16.71Momenta Pharmaceuticals$.654.05%MNTA
Earnings Whisper ®
N/A
3rd Quarter September 2015
Consensus: ($0.13)
Revenue: $35.50 Mil
Thursday
Nov 5
8:00 AM ET
Score
Grade
Tweet Share
Just found this. Whisper numbers.
"3rd Quarter September 2015
Consensus: ($0.13)
Revenue: $35.50 Mil”
This would be a .17 cent improvement from last quarter if it comes in like this. -.04 to +.13 a share.
Expected Earnings release 11/5
What might give added pop to this quarter is, we will have broken into the black for the quarter. The big question on all stocks is can you bring profit to the bottom line.
There are a ton of stocks selling much higher than MNTA that have big negative earnings. I know the potential. Yes, sometimes. My wise broker says it doesn’t mean anything if a company can’t bring a profit to the bottom line. 10 Mass Biotech stocks collapsed in the last two months.
We are ahead of them on just starting to reach our potential and will have profit to the bottom line. Plus we have more shares outstanding now which impacts the earnings per share.
Oct/1 added Glatopa first line.
http://www.myriversidehealth.com/Portals/0/Files/Upcoming%20Formulary%20Changes%20Provider%20Notification%2010-1-2015.pdf
Added 9/1
http://www.aetnabetterhealth.com/ny/assets/pdf/members/formulary-updates/NY%20Duals-2015%20Formulary%20Updates%20Sept2015.pdf
Check out Stiff Person Syndrome (SPS), Never new that disease existed. A very interesting disease that makes one afraid of noise as well as making them stiff. I relate to loud noises making me jump in my old age.
It might be one of many perfect uses for our HSIVIg, once approved, and at a much lower price I would suspect.
Boing X 2
marthambles,
You are welcome.
Boing X 2
"Payers Expected To Push Use Of Sandoz's Glatopa"
Might want to read the PR. I posted from today.
I think we might be seeing signs of that already. Teva had years to drop the drug price and kept on increasing the price. I suspect is why we are seeing these comments. I am sure are price will come down when Sandoz thinks it is appropriate.
Should make for an interesting cc this quarter. Speaking of which, there are only two days left to the quarter.
Boing X 2
imnot6,
Sorry, I missed your post. I do believe you are right and we will likely see more of this in the future.
It sort of goes along with the PR I just posted.
Boing X 2
Added today.
I have had a large bid in for months. It executed today. I know it might go lower but, I am happy as I thought my broker was wrong that I would get the shares at 15.90.
While I was holding my breath I started to see large bids coming in to buy.
Luck to all longs here.
Boing X 2
imnot6,
Great find. Not one of those I found. That is great news! They are big.
Boing X 2
Tony,
Thank you.
This is an international conference and many US doctor's will be there or there by video conferencing.
Boing X 2
Some new information,
Major MS Seminar coming up in Spain,
Oct 7, 2015 - The impact of 2015 criteria for Neuromyelitis optica spectrum disorders ...... An open-label add-on trial of cetirizine for neuromyelitis optica: baseline data and ..... Comparative gene expression profiling between Glatopa™ and.
Sorry, My eyes could not take trying to find the subject in 124 pages. I tried twice.
http://www.professionalabstracts.com/ectrims2015/programme-ectrims2015.pdf
Other news,
Added Oct
http://www.myriversidehealth.com/Portals/0/Files/Upcoming%20Formulary%20Changes%20Provider%20Notification%2010-1-2015.pdf
https://www.valleyhealthplan.org/sites/grp/pn/Pharm/Documents/Pharmacy/VHP_EMP_Formulary%2009.01.2015%20MSP.pdf
Glatopa Tier 1 and Copaxone moved to Tier 3,
https://securews.bcbswny.com/web/content/dam/COMMON/Drug%20Therapy%20Guidelines/Formulary%20Updates/Exclusive%20Formulary%20Updates.pdf
Added 9/1
http://www.sfhp.org/files/providers/formulary/SpecialtyDrugListUpdateSummary.pdf
https://www.ucare.org/SiteCollectionDocuments/HealthPlans/UFS/2015/U6423A_WebsiteFormularyChangeAdditions_UFSGroup.pdf
Boing X 2
Let me see!
I spent two hours researching, digging out and posting the information below after a couple of board members complained about United Health Care Tier 5 and how it was too high and we should not be allowed to have the drug.That the drug should stay with the same company forever. I had to go through each state to find the information copy and compile the information.
I thought I posted a pretty impressive names on Glatopa Preferred list, and Tier 3 lists if I do say so myself. Did those who complain expend any effort to do any search before they complained?
Not one comment, not one kiss my grits. I am not going to spend my time and effort again. It was a lot of work and eye strain for nothing if one does not hear one comment. I stand by my future growth comments. Not looking for glory but, just that someone recognized the effort. As I am retired, I have more time to search for what is happening.
I am not wasting my time though.
We attended a funeral today for a friends pancreatic cancer death.
We found out about his condition, at dinner with his wife, the day we got fast track status for our new drug. Not fast enough. I told his wife that night 9 months ago but, he was already scheduled for chemo so he would not qualify.
He did make it from Dec. which is better than most stage 4 cancers.
What a beautiful family with two children anyone could be proud of to have as parents. The father taught the son his business and now it is up to him at 22 to make the business continue.
Better luck to the next person who finds out they have pancreatic cancer and can sign up for our fast track program early.
Thanks Pollyonwog for the update as I could not listen to the cc today. Interesting on the scripts. If lower is being reported then we are likely higher.
Boing X 2
Just a sample of Glatopa as the Preferred drug,
"
American Express Express Scripts PBM Commercial NY Employer Tier 1 Preferred
American International Group (AIG) Express Scripts PBM Commercial NY Employer Tier 1 Preferred
PepsiCo (Pepsi Company Incorporated) Express Scripts PBM Commercial NY Employer Tier 1 Preferred
OfficeMax Express Scripts PBM Commercial IL Employer Tier 1 Preferred
Sears Holdings Corporation Express Scripts PBM Commercial IL Employer Tier 1 Preferred
HSN, Inc. Express Scripts PBM Commercial FL Employer Tier 1 Preferred
Pinellas County Florida Employees Express Scripts PBM Commercial FL Employer Tier 1 Preferred
CIGNA HealthCare of California POS Single Copay Closed CIGNA Health Plans, Inc. Commercial CA POS Approved Preferred
Motion Picture Health & Welfare Express Scripts PBM Commercial CA Employer Tier 1 Preferred
Pacific Gas and Electric Express Scripts PBM Commercial CA Employer Tier 1 Preferred
Writers Guild Industry Health Fund Express Scripts PBM Commercial CA Employer Tier 1 Preferred
Blue Cross Blue Shield of Massachusetts Blue Care Elect Blue Cross Blue Shield of Massachusetts Commercial MA PPO Tier 1 Preferred "
Quite a large number of the plans have the drug in lower than Tier 5 Many have it in Tier 3
"AMR Corporation Express Scripts PBM Commercial TX Employer Tier 1 Preferred
7-Eleven Express Scripts PBM Commercial TX Employer Tier 3 Covered
BP Amoco Express Scripts PBM Commercial TX Employer Tier 3 Covered
Borden Dairy Company Express Scripts PBM Commercial TX Employer Tier 3 Covered
Continental Airlines Express Scripts PBM Commercial TX Employer Tier 3 Covered
Tenet Healthcare Express Scripts PBM Commercial TX Employer Tier 1 Preferred
Goodyear Tire & Rubber Company Express Scripts PBM Commercial OH Employer Tier 1 Preferred
Cigna approved Glatopa as preferred most states,
CIGNA HealthCare of Ohio POS Two Tier Open CIGNA Health Plans, Inc. Commercial OH POS Tier 1 Preferred
United Parcel Service CVS Caremark RX Commercial GA Employer Tier 3 Covered "
Boing X 2
DewDiligence,
Thank you.
Boing X 2
I am sure this is just a sample. I was getting cross eyed going through the lists.
Another Glatopa added effective 9/1
Page 1
https://www.ucare.org/SiteCollectionDocuments/HealthPlans/UFS/2015/U6423A_WebsiteFormularyChangeAdditions_UFSGroup.pdf
Another effective 9/1 page 19,
http://preciserxcare.amwins.com/ldi/Documents/PreciseRxCare_4Tier_Changes.pdf
Added 8/25
https://www.azblue.com/~/media/azblue/files/pharmacy-forms-mastery-directory/all-other/other-forms-and-resources/specialty-drug-list.pdf
Added 9/1 page 27,
https://www.wpsic.com/partd/files/2015/S5753_26651_021_1407-pdp-formulary-Combined.pdf
NOTE Glatopa Tier 2 vs Copaxone Tier 5
Added 9/1 Top of page,
https://www.priorityhealth.com/medicare/once-you-enroll/drug-coverage/formulary-changes
Added 9/1 page 19
http://www.sterlingretireescripts.com/Documents/Base%20Sterling%20Formulary%20Changes.pdf
Added 9/1 page 2
https://www.mcsclassicare.com/en/Documents/Formulary3Ad2015.pdf
Note other drugs do not apply. i.e. Copaxone? Sole approval for Glatopa?
Added 9/1 page 14
https://www.uamedicarepartd.com/PDF/Formulary/UA_Essential_PriorAuthorization_2015.pdf
Added 9/1 page 37
http://coventry-medicare.coventryhealthcare.com/web/groups/public/@cvty_commoncontent/documents/webcontent/a302055.pdf
Added 9/1 page 24
https://www.partdkansascity.com/shop/content/olspublic/pdf/2015/english/PDP_ComForm_Pre_KC_MO.pdf
Added 9/1 page 74
https://www.modahealth.com/pdfs/odsadv/2015/formulary.pdf
Boing X 2
DewDillengence,
Thank you for the clarification.
They still ramp up based on how sales are going. They don't just go produce 1M injections ahead of realistic sales growth. So earlier sales prices may well be higher. My thoughts.
Boing X 2
pollyvonwog,
I agree.
That doesn't mean MNTA doesn't have the ability to give there input as a working team as to their thoughts. Sandoz likely has the final say.
I think production ramp up is the main reason that the price remains high right now. They want to keep ahead of growth without over expanding too fast. It takes time to brew a batch of the drug and they are already cranking out 30K injections a week and growing.
We don't know what their initial production capacity is while they are ramping up the production. I think I remember on a CC that it was mentioned there was a limit early on for production.
Questions that would help are, how many injections does one batch produce? What is their production capacity for one week at the current time? Are they working more than one shift right now? Three shifts? What is the expansion time frame? How many batches of Glatopa can they brew at one time?
How much down time on the production line in one year? 30K vials is a bunch each week in a sterile environment and growing.
If they would say we can produce x amount of injections is a week without further expansion it would be a help. Not sure they will say that though.
Not long and we might get some feedback on the 18th with the Morgan Stanley conference.
Boing X 2